Indications
Palynziq is indicated for the treatment of patients with phenylketonuria (PKU) aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 micromol/l) despite prior management with available treatment options.
Composition
- Active substance
- pegvaliase
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Palynziq
- Active substance
- pegvaliase
- ATC code
- A16AB19
- Therapeutic area
- Phenylketonurias
- Marketing authorisation holder
- BioMarin International Limited
- Status